CIDARA THERAPEUTICS INC (CDTX) Forecast, Price Target & Analyst Ratings
NASDAQ:CDTX • US1717572069
221.38 USD
+0.06 (+0.03%)
At close: Jan 6, 2026
221.38 USD
0 (0%)
After Hours: 1/6/2026, 8:19:29 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CIDARA THERAPEUTICS INC (CDTX).
Forecast Snapshot
Consensus Price Target
$220.19
-0.54% Downside
Next Earnings Forecast
Release DateMar 4, 2026
PeriodQ4 / 2025
EPS Estimate-$1.54
Revenue Estimate
ChartMill Buy Consensus
74.29%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$220.19
Upside
-0.54%
From current price of $221.38 to mean target of $220.19, Based on 14 analyst forecasts
Low
$200.99
Median
$225.93
High
$232.58
Price Target Revisions
1 Month
0.00%
3 Months
63.96%
Price Target Summary
14 Wall Street analysts provided a forecast for the next 12 months for CDTX. The average price target is 220.19 USD. This implies a price decrease of -0.54% is expected in the next year compared to the current price of 221.38.
The average price target has been revised upward by 63.96% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
74.29%
CDTX was analyzed by 14 analysts. The buy percentage consensus is at 74. So analysts seem to be have mildly positive about CDTX.
In the previous month the buy percentage consensus was at a similar level.
CDTX was analyzed by 14 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-11-18 | Guggenheim | Downgrade | Buy -> Neutral |
| 2025-11-14 | Needham | Downgrade | Buy -> Hold |
| 2025-11-14 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2025-11-07 | Needham | Maintains | Buy -> Buy |
| 2025-11-07 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-10-21 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-10-16 | Morgan Stanley | Initiate | Overweight |
| 2025-10-10 | JP Morgan | Initiate | Overweight |
| 2025-10-09 | WBB Securities | Maintains | Strong Buy -> Strong Buy |
| 2025-10-09 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-10-03 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2025-09-26 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-09-25 | Guggenheim | Maintains | Buy -> Buy |
| 2025-09-24 | WBB Securities | Reiterate | Strong Buy -> Strong Buy |
| 2025-09-24 | Needham | Maintains | Buy -> Buy |
| 2025-09-22 | WBB Securities | Maintains | Strong Buy -> Strong Buy |
| 2025-08-08 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2025-08-08 | Needham | Maintains | Buy -> Buy |
| 2025-08-08 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-06-30 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2025-06-24 | Guggenheim | Maintains | Buy -> Buy |
| 2025-06-24 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-06-23 | WBB Securities | Reiterate | Strong Buy -> Strong Buy |
| 2025-06-23 | Needham | Maintains | Buy -> Buy |
| 2025-06-10 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
Next Earnings Forecast Details
Next Earnings Details
Release DateMar 4, 2026
PeriodQ4 / 2025
EPS Estimate-$1.54
Revenue Estimate
Revenue Q2QN/A
EPS Q2Q71.35%
Number of Analysts10
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
4.01%
Next Earnings Summary
CDTX is expected to report earnings on 3/4/2026. The consensus EPS estimate for the next earnings is -1.54 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 64.448M 30.01% | 63.905M -0.84% | 1.275M -98.00% | -100.00% | 8.597M | 10.232M 19.02% | 390.39M 3,715.38% | 824.06M 111.09% | 1.278B 55.09% | 1.662B 30.05% | 2.202B 32.49% | 2.736B 24.25% | |
| EBITDA YoY % growth | -33.36M 20.70% | -24.365M 26.96% | -90.986M -273.43% | -193.951M -113.17% | -238.523M -22.98% | -218.143M 8.54% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -33.503M 20.71% | -24.483M 26.92% | -91.219M -272.58% | -193.804M -112.46% | -207.459M -7.05% | -230.893M -11.30% | 58.888M 125.50% | 386.78M 556.81% | 717.74M 85.57% | 1.071B 49.22% | 1.482B 38.38% | 1.991B 34.35% | |
| Operating Margin | -51.98% | -38.31% | -7,154.43% | N/A | -2,413.16% | -2,256.58% | 15.08% | 46.94% | 56.16% | 64.44% | 67.30% | 72.77% | |
| EPS YoY % growth | -9.60 42.86% | -4.80 50.00% | -11.49 -139.37% | -8.30 27.77% | -6.40 22.83% | -6.48 -1.23% | 0.70 110.80% | 7.44 961.60% | 14.71 97.85% | 23.65 60.78% | 30.04 26.99% | 37.72 25.57% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -1.54 71.35% | -1.37 17.66% | -1.60 3.25% | -1.89 38.96% | -2.27 -47.49% |
| Revenue Q2Q % growth | |||||
| EBITDA Q2Q % growth | -51.255M 4.99% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -48.529M 10.43% | -30.6M -21.10% | -30.6M -11.74% | -31.62M 27.52% | -31.62M 34.84% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
12.81%
EPS Next 5 Year
21.49%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
13.33%
Revenue Next 5 Year
159.31%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
-11.38%
EBIT Next 5 Year
N/A
CIDARA THERAPEUTICS INC / CDTX Forecast FAQ
What is the average price target for CIDARA THERAPEUTICS INC (CDTX) stock?
14 analysts have analysed CDTX and the average price target is 220.19 USD. This implies a price decrease of -0.54% is expected in the next year compared to the current price of 221.38.
When does CIDARA THERAPEUTICS INC (CDTX) report earnings?
CIDARA THERAPEUTICS INC (CDTX) will report earnings on 2026-03-04, after the market close.
What are the consensus estimates for CIDARA THERAPEUTICS INC (CDTX) next earnings?
The consensus EPS estimate for the next earnings of CIDARA THERAPEUTICS INC (CDTX) is -1.54 USD and the consensus revenue estimate is 0 USD.
How many analysts cover CIDARA THERAPEUTICS INC (CDTX) stock?
The number of analysts covering CIDARA THERAPEUTICS INC (CDTX) is 14.